Advertisement

Targeting NAD(P)H:Quinone oxidoreductase (NQO1) in pancreatic cancer

Authors

  • Anne M. Lewis,

    1. The University of Iowa College of Medicine, Iowa City, Iowa
    Search for more papers by this author
  • Matthew Ough,

    1. The University of Iowa College of Medicine, Iowa City, Iowa
    Search for more papers by this author
  • Juan Du,

    1. Departments of Radiation Oncology, The University of Iowa College of Medicine, Iowa City, Iowa
    Search for more papers by this author
  • Ming-Sound Tsao,

    1. Department of Pathology and Division of Cellular Molecular Biology and the Ontario Cancer Institute/Princess Margaret Hospital Toronto, and University of Toronto, Ontario, Canada
    Search for more papers by this author
  • Larry W. Oberley,

    1. Departments of Radiation Oncology, The University of Iowa College of Medicine, Iowa City, Iowa
    Search for more papers by this author
  • Joseph J. Cullen MD

    Corresponding author
    1. Departments of Surgery, The University of Iowa College of Medicine, Iowa City, Iowa
    2. Departments of Radiation Oncology, The University of Iowa College of Medicine, Iowa City, Iowa
    3. The University of Iowa College of Medicine, Iowa City, Iowa
    4. Veterans Affairs Medical Center, Iowa City, Iowa
    • 4605 JCP, The University of Iowa Hospitals and Clinics, Iowa City, IA 52242.
    Search for more papers by this author

Abstract

NAD(P)H:Quinone oxidoreductase (NQO1) functions as an important part of cellular antioxidant defense by detoxifying quinones, thus preventing the formation of reactive oxygen species. The aims of our study were to determine if NQO1 is elevated in pancreatic cancer specimens and pancreatic cancer cell lines and if so, would compounds previously demonstrated to redox cycle with NQO1 be effective in killing pancreatic cancer cells. Immunohistochemistry of resected pancreatic specimens demonstrated an increased immunoreactivity for NQO1 in pancreatic cancer and pancreatic intraepithelial neoplasia (PanIN) specimens versus normal human pancreas. Immunocytochemistry and Western immunoblots demonstrated inceased immunoreactivity in pancreatic cancer cells when compared to a near normal immortalized human pancreatic ductal epithelial cell line and a colonic epithelial cell line. Streptonigrin, a compound known to cause redox cycling in the presence of NQO1, decreased clonogenic survival and decreased anchorage-independent growth in soft agar. Streptonigrin had little effect on cell lines with absent or reduced levels of NQO1. The effects of streptonigrin were reversed in pancreatic cancer cells pretreated with dicumarol, a known inhibitor of NQO1. NQO1 may be a therapeutic target in pancreatic cancer where survival is measured in months. © 2006 Wiley-Liss, Inc.

Ancillary